Rehabilitation Research News:
May 16, 2022

Thank you to everyone who attended the National Advisory Board for Medical Rehabilitation Research (NABMRR) meeting on May 2 and 3. The speakers and discussions were excellent. If you weren’t able to attend, please see the videos on the NIH VideoCast archive for Day 1 and Day 2.
 
I particularly want to thank the four NABMRR members who have completed their terms for their incredible service to the Board: Art English, Thubi Kolobe, Barbara Lutz, and Robert Wudlick.
 
The next session in the Medical Rehabilitation Research Speaker Series, Assistive and Rehabilitation Technology, will take place Friday, May 20, 2022, at 12 p.m. ET. The speakers will be Martina Mancini, Ph.D., of the Oregon Health & Science University, and Lynn Worobey, Ph.D., D.P.T., ATP, of the University of Pittsburgh. To find more information and register for this free event, visit the Medical Rehabilitation Research Speaker Series: Assistive and Rehabilitation Technology page under Scientific Meetings and Events.
 
As rehabilitation trials become more invasive, the need for principal investigators to plan for participants’ responsibilities beyond the trial period has increased. Please join the NIH Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative Neuroethics Working Group (NEWG) Workshop on Continuing Trial Responsibilities on May 24 and 25 to hear discussions from stakeholders and experts. The working group consists of a group of experts in neuroscience and its ethical, legal, and societal implications (neuroethics); the group provides the NIH BRAIN Initiative with input relating to neuroethics. The aim of this workshop is to bring relevant stakeholders together to discuss research-related care needs for participants in neural device trials after the trials end. For more information on the agenda and how to register, please visit the NEWG workshop page. 

NIH Research Opportunity Announcement (ROA) for Clinical Trials for the Prevention and/or Treatment of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

As part of the Researching COVID to Enhance Recovery (RECOVER) Initiative, NIH is soliciting applications for clinical trials in individuals more than 18 years old for the prevention and/or treatment of PASC. NIH is seeking proposals for clinical trials testing a range of interventions and using diverse methods to address symptoms/symptom clusters and the underlying mechanisms of the pathobiology of PASC. Trial proposals should reflect community and patient engagement. The funding will use NIH’s Other Transaction Authority (OTA). Learn more about this ROA at recovercovid.org .

For More Information: If you have questions that are not answered within the ROA, please direct them to NHLBI_OTA@mail.nih.gov.

NIH Research Education Program Funding Opportunity Announcement (FOA): Education Program on Translational Devices (R25 Clinical Trial Not Allowed)

The National Institute of Neurological Disorders and Stroke, in partnership with the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug Abuse, and the National Cancer Institute, invites R25 applications to develop and implement a short course focused on (1) steps required for successful neural medical device development, translation, and commercialization; (2) common technical and strategic challenges; and (3) best practices and resources for each stage in the process. Applicants may choose to include a plan for extended engagement opportunities for participants to continue to interact with and obtain guidance from faculty members after the conclusion of the course. The short course should address a broad audience, including senior postdoctoral fellows, independent academic researchers, clinician scientists, and small business entrepreneurs interested in developing, translating, and/or commercializing medical devices to diagnose or treat a nervous system disorder.

How to Apply: Applications should be submitted by the due date of July 29, 2022. Access the FOA (PAR-22-146) to learn more. Please direct all questions and comments to Brooks Gross, Ph.D.